We evaluated the precision of BANF1 as a predictor of treatment outcome in five cohorts of patients with HNSCC treated with ICB and contrasted it with other established biomarkers related to tumor immune evasion. The gene discussed is BANF1; the disease is head and neck squamous cell carcinoma.